Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely...

Area of Science:

• Immunology
• Endocrinology
• Diabetes Research

Background:

• T cells are central to type 1 diabetes pathogenesis.
• Anti-CD3 antibody therapy shows promise in reversing diabetes in mouse models.
• The precise mechanisms of anti-CD3 therapy, particularly regarding T cell depletion versus functional modulation, require further elucidation.

Purpose of the Study:

• To investigate the in vivo effects of anti-CD3 treatment on islet-specific effector T cells.
• To determine whether anti-CD3 therapy selectively depletes pathogenic T cells or modulates their function.
• To explore the role of Programmed cell death protein 1 (PD-1) and its ligand (PD-L1) in anti-CD3 mediated protection.

Main Methods:

• Utilized a mouse model with transferred green fluorescent protein (GFP)+ islet-specific effector T cells.
• Assessed T cell presence, gene expression, and cytokine production in various organs during anti-CD3 treatment.
• Analyzed the impact of anti-PD-L1 antibody on diabetes and its reversal by anti-CD3 therapy.

Main Results:

• Anti-CD3 treatment did not preferentially deplete transferred effector T cells.
• Anti-CD3 therapy inhibited effector T cell metabolic function and interferon-gamma production.
• PD-1 expression increased on effector T cells; anti-CD3 reversal of anti-PD-L1 induced diabetes depended on treatment duration, suggesting a role for PD-1/PD-L1 interaction.

Conclusions:

• Anti-CD3 therapy reverses type 1 diabetes by functionally inhibiting pathogenic T cells rather than through selective depletion.
• The PD-1/PD-L1 pathway is crucial for the protective effects of anti-CD3 antibody treatment.
• These findings reveal an additional mechanism for anti-CD3 therapy in reversing diabetogenesis.